Page 20 - AnnualReport2022-23

Project Title Principal Investigator Institution
Impact of Covid-19 on clinical manifestations, Prof. Bavesh Kana University of the
diagnosis, treatment outcome and immune response Witwatersrand & National
for pulmonary tuberculosis (Nickname: ABRICOT – Health Laboratory Services
Associative BRICS Research in Covid-19 and
Tuberculosis)

Epidemiological impact and intersection of the Prof. Anneke C Hesseling Stellenbosch
COVID-19 and tuberculosis pandemics in Brazil, University
Russia, India and South Africa

Repurposing of drugs and validation of lead Prof. Anil Chuturgoon, University of
compounds against main protease and RNA KwaZulu-Natal
dependent RNA polymerase of SARS-CoV2

BRICS Multilateral Joint Science • Simulation and big data analytics for advanced
and Technology Research precision medicine and public healthcare
Collaboration – 2021 Call for Eighteen (18) full proposals were reviewed and
Joint Project Proposals of the four (4) joint projects selected for funding
in the thematic area ‘Antimicrobial resistance:
The BRICS STI Framework Programme (FP) aims to
support excellent research in priority areas which technologies for diagnosis and treatment’, three (3)
can best be addressed by a multinational approach. have a SA component. No projects were selected
To this end, a call for joint project proposals in ten for funding in the thematic area ‘Simulation and big
(10) thematic areas was launched in 2021. data analytics for advanced precision medicine and
public healthcare’.
DSI invited the SAMRC to manage the call in the
following two thematic areas: The three (3) selected projects to commence on
1 April 2023 and end on 31 March 2026 are:
• Antimicrobial resistance: technologies for
diagnosis and treatment

Project Title Principal Investigator Institution
Novel siderophore fragments and hybrids Prof Rui Krause Rhodes University
for the diagnosis and treatment of drug resistant-
infectious pathogens

Unlocking bacterial resistance to antibiotics with the Associate University of
development of novel metallo-β-lactamase inhibitors Prof Tricia Naicker KwaZulu-Natal

Target identification and efficacy enhancement of proven Dr Awelani Mutshembele South African Medical
MDR overcoming Piper spp derived compounds towards Research Council,
candidate drug development against WHO priority TB Platform
1 (critical) MDR pathogens: P. aeruginosa, E. coli, K.
pneumoniae, and M. tuberculosis

18 SAMRC ANNUAL REPOR T 2022-23